Statements (67)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Canis_lupus
|
| gptkbp:affects |
central nervous system
|
| gptkbp:associated_with |
gptkb:systemic_lupus_erythematosus
|
| gptkbp:clinical_trial |
gptkb:depression
gptkb:neurodegenerative_diseases financial difficulties anxiety fatigue sleep disturbances substance abuse confusion social anxiety bipolar disorder memory loss disorientation legal issues paranoia headaches academic challenges apathy social withdrawal family stress hallucinations movement disorders tremors relationship problems attention deficits healthcare access issues neuropathy delusions delirium agitation personality changes visual disturbances emotional lability suicidal ideation community stigma executive dysfunction language difficulties catatonia obsessive-compulsive symptoms psychomotor retardation interpersonal difficulties schizophrenia-like symptoms self-harm behavior visual-spatial deficits work-related issues |
| gptkbp:complication |
increased mortality
functional impairment |
| gptkbp:diagnosis |
clinical evaluation
neuroimaging |
| https://www.w3.org/2000/01/rdf-schema#label |
neuropsychiatric lupus
|
| gptkbp:prevalence |
varies by population
|
| gptkbp:research_focus |
gptkb:sports_equipment
treatment efficacy pathophysiology |
| gptkbp:risk_factor |
age
female gender |
| gptkbp:symptoms |
seizures
mood disorders psychosis cognitive dysfunction |
| gptkbp:treatment |
antidepressants
corticosteroids immunosuppressants |
| gptkbp:bfsParent |
gptkb:ACR_guidelines_for_lupus
|
| gptkbp:bfsLayer |
7
|